Minovar (603538.SH) announced semi-annual results, with net profit of 63.6891 million yuan, an increase of 29.83% over the previous year

According to Zhitong Finance App News, Minova (603538.SH) released its 2026 semi-annual report. During the reporting period, the company achieved operating income of 859 million yuan, an increase of 26.79%; net profit attributable to shareholders of listed companies was 63.689 million yuan, an increase of 29.83% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 63.3989 million yuan, an increase of 72.5% year on year; basic earnings per share were 0.26 yuan.

In the first half of 2026, against the backdrop of an increasingly severe international political and economic situation, the company actively responded to changes in the internal and external environment and optimized the overall business model. Continue to increase the integrated layout of “intermediates - APIs - formulations” and open up competition throughout the industry chain. In terms of the formulation business, during the reporting period, the company's pharmaceutical products were launched one after another, entering a period of rapid development, achieving formulation revenue of 325 million yuan, an increase of 24.05% over the reporting period; in the API business, due to geopolitical conflicts, upstream raw material costs rose, and terminal products faced price pressure and competition in the Indian industrial chain during the inventory removal cycle. Revenue during the reporting period was 452 million yuan, an increase of 29.51% year on year.